Nurix Therapeutics, Inc. (NRIX)
26.21
-0.66
(-2.47%)
USD |
NASDAQ |
Aug 28, 16:00
26.19
-0.02
(-0.08%)
After-Hours: 20:00
Nurix Therapeutics Free Cash Flow : -304.53M for May 31, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| May 31, 2026 | -304.53M |
| February 28, 2026 | -271.85M |
| November 30, 2025 | -263.47M |
| August 31, 2025 | -241.36M |
| May 31, 2025 | -225.79M |
| February 28, 2025 | -201.59M |
| November 30, 2024 | -181.86M |
| August 31, 2024 | -106.90M |
| May 31, 2024 | -105.96M |
| February 29, 2024 | -83.87M |
| November 30, 2023 | -89.77M |
| August 31, 2023 | -154.39M |
| May 31, 2023 | -160.52M |
| February 28, 2023 | -176.68M |
| Date | Value |
|---|---|
| November 30, 2022 | -172.05M |
| August 31, 2022 | -163.30M |
| May 31, 2022 | -145.42M |
| February 28, 2022 | -143.34M |
| November 30, 2021 | -90.03M |
| August 31, 2021 | -79.64M |
| May 31, 2021 | -55.62M |
| February 28, 2021 | -38.03M |
| November 30, 2020 | -4.633M |
| August 31, 2020 | 3.054M |
| May 31, 2020 | 46.74M |
| February 29, 2020 | 49.40M |
| November 30, 2019 | -1.05M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Monte Rosa Therapeutics, Inc. | -32.08M |
| Gilead Sciences, Inc. | 12.94B |
| TG Therapeutics, Inc. | 17.38M |
| Cue Biopharma, Inc. | -50.17M |
| Keros Therapeutics, Inc. | -48.49M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -96.57M |
| Cash from Investing (Quarterly) | 93.00M |
| Cash from Financing (Quarterly) | 0.066M |
| Free Cash Flow Per Share (Quarterly) | -0.8868 |
| Free Cash Flow to Equity (Quarterly) | -98.00M |
| Free Cash Flow to Firm (Quarterly) | -98.51M |
| Free Cash Flow Yield | -11.61% |